This page is for healthcare professionals and other relevant decision makers in the United Kingdom. Information on this page is aligned to the Summary of Product Characteristics.

Search

Menu

Close

Sign InLog Out
Pfizer MedicinesTherapy areasExplore contentEventsVideosMaterialsFeatured ArticlesLet’s connectSupplyAlliance HealthcareOff-contract claims

Menu

Close

How to orderResourcesMaterialsVideosEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

For Prescribing Information on COMIRNATY®▼ vaccines available for use in the private market, please click here. Adverse event reporting information can be found at the bottom of the page.

Virtual Meeting Invitation
Spotlight on COVID-19 and Implementing a Private Vaccination Service

A promotional meeting organised and funded by Pfizer which will include reference to Pfizer medicines relevant to the agenda topics.

This meeting is intended for healthcare professionals resident in the United Kingdom.

Title
Register to attend

Please e-mail [email protected] or call 07771 938 293 to confirm your attendance to this meeting.

Please include the date and time in your response and provide a work email address for joining instructions to be sent to
Event Agenda
This promotional meeting is organised and funded by Pfizer Ltd. Please note that, under the law and the ABPI Code of Practice, Pfizer may only provide hospitality and/or promote its medicines to members of the healthcare professions and other relevant decision makers. Therefore, no unqualified person (e.g., medical students, non-medical spouses, partners) may be invited to or attend Pfizer meetings.

The meeting will be broadcast via a virtual platform enabling you to join the meeting from your own computer or mobile device and will allow you to receive audio and video streaming of the speaker presentations and pose questions to the speakers. We ask that you ensure that you are in a private location when joining the virtual meeting and that no unqualified persons or members of the public are able to hear or view the meeting content.

References

COMIRNATY KP.2 30 microgram/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine Summary of Product Characteristics; Pfizer and BioNTech. Available at: https://www.medicines.org.uk/emc/product/100164/smpc
PP-CMR-GBR-0798. February 2025

Adverse Event Reporting

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. 

Healthcare professionals are asked to report any suspected adverse reactions via a Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.

Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

Marketing Authorisation
Holder: BioNTech
Manufacturing GmbH

COMIRNATY COVID-19 mRNA Vaccines, which are based on BioNTech proprietary mRNA technology, were developed by both BioNTech and Pfizer.


The product information provided in this site is intended only for Healthcare Professionals and Other Relevant Decision Makers resident in the United Kingdom. 


This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ.

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427
 

 

PP-CMR-GBR-0791. February 2025

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​